Skip to main content

We offer

Innovative screening technologies

DNA encoded library screening in living cells

High Fidelity Drug Discovery – Get an early lead

Proprietary technology platforms

At Vipergen, we utilize innovative, proprietary technologies to transform drug discovery. By enabling screening directly in living cells under physiologically relevant conditions, we expand the target space, improve efficiency, and accelerate lead generation. Our patented platforms set a new standard for tackling even the most complex drug targets.

World-leading provider of small molecule drug discovery services based on DNA-encoded library technologies

Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies. Vipergen is offering different business models, including simple Fee-For-Service.

What we do

How we do it

Who we are

Do you have an inquiry?

From straightforward Fee-For-Service to comprehensive joint ventures, we provide flexible partnership structures to align with your project’s distinct needs.

  • Innovative screening technologies with Cellular Binder Trap Enrichment (cBTE) & Binder Trap Enrichment (BTE)
  • Vipergen’s approach enables the discovery of novel molecules directly in living cells, improving hit rates and drug development efficiency.
  • Vipergen owns exclusive rights to its technology platforms, including YoctoReactor®, BTE, and cBTE, all secured by strong patent positions

Cellular Binder Trap Enrichment (cBTE)

  • 3rd generation screening technology
  • Screening inside a living cell (unique capability)
  • Physiologically relevant conditions
  • Lower attrition rate
  • No need for purified target protein (unique capability)
  • Broader protein target space
  • Multiplexing (unique capability)

Binder Trap Enrichment (BTE)

  • 2nd generation screening technology
  • Solution based (homogenous assay)
  • No matrix binders
  • No target denaturation by immobilization
  • Low false positive rate
  • Multiplexing (unique capability)

YoctoReactor (yR)

  • 2nd generation library synthesis technology
  • Chemical diversity by building blocks
  • Physicochemical properties kept in check
  • 100% match between code and compound
  • Purification after each synthesis step (unique capability)
  • Low false positive rate